Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer’s disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.
| Metrics to compare | NXL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNXLPeersSector | |
|---|---|---|---|---|
| P/E Ratio | −3.3x | −1.3x | −0.7x | |
| PEG Ratio | −0.77 | −0.03 | 0.00 | |
| Price/Book | 4.9x | 1.2x | 2.6x | |
| Price / LTM Sales | 167.4x | 4.8x | 3.4x | |
| Upside (Analyst Target) | 158.1% | 8.1% | 40.0% | |
| Fair Value Upside | Unlock | 24.9% | 6.9% | Unlock |